Prediction of Survival Time for Patients with Lung Cancer and Assessment of Therapeutic Effect

Katsuo Usuda, Tutomu Sakuma, Masashi Handa, Gunji Okaniwa, Tasuku Nakada, Yasuki Saito, Chiaki Endo, Motoyasu Sagawa, Masami Sato, Shigefumi Fujimura

Research output: Contribution to journalArticle

Abstract

Predicted survival time was calculated based on tumor size and growth rate using the Geddes' nomogram in 174 patients with primary lung cancer, and the obtained predicted survival time was compared with actual survival time in each case. Predicted survival curves based on predicted survival time were compared with actual survival curves. In 48 patients who did not undergo resection, multivariate analyses using Cox's proportional hazard model were used to evaluate the risk of death related to predicted survival time and other prognostic factors. There was no significant correlation between actual survival time and predicted survival time. In patients who did not undergo resection, the actual survival curve was similar to the predicted survival curve. On the other hand, in patients who underwent resection, the actual survival curve was significantly better than the predicted survival curve (p < 0.0001). The predicted survival time was proved to be useful to evaluate therapeutic effect. Multivariate analyses using Cox's proportional hazard model identified three significant variables : N factor (p=0.0011); M factor (p = 0.0146); predicted survival time (p = 0.0265). Predicted survival time was a significant prognostic factor in patients who did not undergo resection.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalHaigan
Volume35
Issue number1
DOIs
Publication statusPublished - 1995 Jan 1

Keywords

  • Cox's proportional hazard model
  • Geddes' nomogram
  • Predicted survival time
  • Primary lung cancer
  • Tumor doubling time

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Prediction of Survival Time for Patients with Lung Cancer and Assessment of Therapeutic Effect'. Together they form a unique fingerprint.

Cite this